



GLOBAL BOARD OF DIRECTORS

Baxter BioScience
Lawrence P. Guiheen, Chair

Biotest AG
Gregor Schulz

CSL Behring
Paul Perreault

Grifols
David Bell

Kedrion
Paolo Marcucci

General Counsel
Paul Rosenthal, Esq.

PPTA STAFF

President & CEO
Jan M. Bult

Senior Vice President,
North America
Julie A. Birkofer

Vice President, Europe
Charles Waller

Vice President, Source
Joshua Penrod

THE SOURCE is published four times a year by PPTA, 147 Old Solomons Island Road, Suite 100 Annapolis, MD 21401 Phone: +1.202.789.3100 email: thesource@pptaglobal.org

Requests for permission to translate and/or reprint contents of

THE SOURCE should be directed to the editor at thesource@pptaglobal.org

THE SOURCE is available as a PDF file from the PPTA website at www.pptaglobal.org

In the interest of encouraging broad and open discussion of issues relating to plasma protein therapies, collection and fractionation, THE SOURCE magazine may contain statements of opinion on such issues.

These statements are those of the author and do not necessarily reflect the opinion of PPTA or its members.

©Plasma Protein Therapeutics Association 2011

Design and Production
Tom Heffner
Bonotom Studio, Inc.
www.bonotom.com

INSIDE

WINTER 2011

THE MAGAZINE FOR THE PLASMA PROTEIN THERAPEUTICS INDUSTRY



2 IN MY VIEW
How PPTA Dealt with Shortages

4 PPTA INTERVIEW
Prof. Jean-Louis Vincent, M.D., Ph.D.
Professor of Intensive Care, Université Libre de Bruxelles and the Head of the Department of Intensive Care, Erasme University Hospital.

6 Source Business Forum 2011
Twenty Years of IQPP

8 H.R. 2672: "Preserving Access to Orphan Drugs Act of 2011"
Congressman Jim Gerlach explains his introduction of the Act.

10 PATIENT ADVOCATES
PID Patient Channels Pain of Fighting Illness & Insurance Coverage into Helping Others.

12 What is Discussed Behind Closed Doors?
Interaction between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

16 Working for Patient Access to Blood Clotting Factor
Patient access is always a concern for Medicaid recipients because Medicaid reimbursement is low when compared to private insurance and Medicare.

18 The Global Financial Crisis and the Plasma Protein Patient Community
Troubling indications are emerging that the community of patients needing plasma protein therapies (PPTs) are potentially very vulnerable to its effects.

21 Deficit Reduction Efforts Target Medicare
The Super Committee's failure triggers a statutory procedure known as sequestration, resulting in indiscriminate across-the-board cuts.

24 INSIDE PPTA
PPTA News from Around the Globe

27 Meet the PPTA Staff
Cathy Izzi

28 EVENTS
Upcoming Conferences & Symposiums



These companies have earned QSEAL certification. The PPTA QSEAL program is a promise to stakeholders worldwide, that the highest levels of care were invested into the production of these unique life-saving therapies.

BAXTER BIOSCIENCE
BIOTEST AG
CSL BEHRING
GRIFOLS, S.A.
KEDRION

COVER ART: WEBMINK, JASTAN / ISTOCK, BONOTOM STUDIO

